Recently, a preclinical report assessed the efficacy, safety, and feasibility of using human embryonic stem cells to regenerate infarcted myocardium in a nonhuman primate model. This commentary evaluates that study by pointing out key weaknesses, offering an alternative perspective, and summarizing major unresolved issues. Our conclusion is that significant challenges remain before human embryonic stem cells are ready for use in clinical trials.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Jul 18 2014|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine